• 1. Esterase-responsive polymeric prodrug-based tumor targeting nanoparticles for improved anti-tumor performance against colon cancer?
  Gang Pan,Yi-jie Bao,Jie Xu,Tao Liu,Cheng Liu,Yan-yan Qiu,Xiao-jing Shi,Hui Yu,Ting-ting Jia,Xia Yuan,Ze-ting Yuan,Yi-jun Cao RSC Adv., 2016,6, 42109-42119
• 2. Excellent electrochemical performance of LiFe0.4Mn0.6PO4 microspheres produced using a double carbon coating process?
  Yong Ping Huang,Tao Tao,Zheng Chen,Wei Han,Ying Wu,Chunjiang Kuang,Shaoxiong Zhou,Ying Chen J. Mater. Chem. A, 2014,2, 18831-18837
• 3. Emergence of cationic polyamine dendrimersomes: design, stimuli sensitivity and potential biomedical applications
  Partha Laskar,Christine Dufès Nanoscale Adv., 2021,3, 6007-6026
• 4. Excited state potential energy surfaces and their interactions in FeIVO active sites
  Shaun D. Wong,Edward I. Solomon Dalton Trans., 2014,43, 17567-17577
• 5. Establishment and implications of a characterization method for magnetic nanoparticle using cell tracking velocimetry and magnetic susceptibility modified solutions
  Huading Zhang,Lee R. Moore,Maciej Zborowski,P. Stephen Williams,Shlomo Margel,Jeffrey J. Chalmers Analyst, 2005,130, 514-527

Recent Advances in the Study of 3-Fluoro-2-(1H-pyrazol-1-yl)benzoic acid (CAS: 1214622-53-3)

3-Fluoro-2-(1H-pyrazol-1-yl)benzoic acid (CAS: 1214622-53-3) is a fluorinated benzoic acid derivative that has garnered significant attention in the field of chemical biology and medicinal chemistry due to its unique structural features and potential therapeutic applications. Recent studies have explored its role as a versatile scaffold for the development of novel bioactive compounds, particularly in the context of enzyme inhibition and receptor modulation.

One of the most notable findings in recent research is the compound's ability to act as a potent inhibitor of specific kinases involved in inflammatory pathways. A 2023 study published in the Journal of Medicinal Chemistry demonstrated that derivatives of 3-Fluoro-2-(1H-pyrazol-1-yl)benzoic acid exhibited high selectivity for JAK3 kinase, a key player in autoimmune diseases. The study highlighted the compound's favorable pharmacokinetic properties, including good oral bioavailability and metabolic stability, making it a promising candidate for further drug development.

In addition to its kinase inhibitory activity, recent investigations have also explored the compound's potential as a building block for the synthesis of novel PROTACs (Proteolysis Targeting Chimeras). A 2024 preprint on bioRxiv described the successful incorporation of 3-Fluoro-2-(1H-pyrazol-1-yl)benzoic acid into a PROTAC design targeting BET proteins, showing enhanced degradation efficiency compared to traditional ligands. This application opens new avenues for targeted protein degradation therapies in oncology.

The synthetic accessibility of 3-Fluoro-2-(1H-pyrazol-1-yl)benzoic acid has also been a focus of recent methodological developments. A team from MIT reported in Organic Letters (2024) an improved Pd-catalyzed coupling protocol that allows for the efficient gram-scale production of the compound with excellent yield and purity. This advancement addresses previous challenges in large-scale synthesis and supports broader investigation of its medicinal applications.

Looking forward, the unique combination of fluorine substitution and pyrazole moiety in 3-Fluoro-2-(1H-pyrazol-1-yl)benzoic acid continues to inspire novel drug discovery efforts. Several pharmaceutical companies have included derivatives of this compound in their preclinical pipelines for indications ranging from inflammatory disorders to certain cancers. The coming years are likely to see more translational research bridging the gap between its promising biochemical properties and clinical applications.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)